Coin toss immunity: Glaxo's malaria vaccine

GlaxoSmithKline’s malaria vaccine is possibly better than nothing — but even in the best light, it’s still dilly-dallying.

The GSK-supported PATH Malaria Vaccine Initiative reports in the New England Journal of Medicine that its RTS,S vaccine reduced the incidence of severe malaria by 50% in a population of African children. The immunity provided to the fortunate 50% by the vaccine, however, may wane over time. The vaccine did not reduce the number of malaria deaths, but it’s still too early to draw any conclusions.

The 50-50-chance-of-at-least-temporary-immunity-from-severe-malaria result seems to be encouraging and, if you throw in bed nets, what’s not to like — right? Wrong.

Our view is that the most effective, most direct and least expensive solution to the green-supported malarial genocide is the application of ample insecticides — preferably safe, effective and low-cost ones like DDT.

Short of this, we are simply navel-gazing while out-of-sight, out-of-mind Africans die largely preventable deaths, social structure is decimated and economic development is crippled.

Read the full NEJM study.
Read the study media release.

2 thoughts on “Coin toss immunity: Glaxo's malaria vaccine”

  1. If the vaccine did not reduce the number of deaths; what good is it?

    SKG developed the vaccine for developed world to pay for as an apology for banning DDT that would cheaply eliminate malaria.

    James Rust

Comments are closed.